Compare Panacea Biotech with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs PIRAMAL ENTERPRISES - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH PIRAMAL ENTERPRISES PANACEA BIOTECH/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 12.6 19.0 66.5% View Chart
P/BV x 3.0 1.2 251.4% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 PANACEA BIOTECH   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-18
PIRAMAL ENTERPRISES
Mar-19
PANACEA BIOTECH/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs3643,303 11.0%   
Low Rs1291,797 7.2%   
Sales per share (Unadj.) Rs96.8716.5 13.5%  
Earnings per share (Unadj.) Rs-12.479.7 -15.6%  
Cash flow per share (Unadj.) Rs-2.9107.9 -2.6%  
Dividends per share (Unadj.) Rs028.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs50.41,477.5 3.4%  
Shares outstanding (eoy) m61.25184.45 33.2%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.53.6 71.6%   
Avg P/E ratio x-19.932.0 -62.1%  
P/CF ratio (eoy) x-86.423.6 -365.8%  
Price / Book Value ratio x4.91.7 283.5%  
Dividend payout %035.1 0.0%   
Avg Mkt Cap Rs m15,101470,292 3.2%   
No. of employees `0002.57.8 31.6%   
Total wages/salary Rs m1,51622,504 6.7%   
Avg. sales/employee Rs Th2,401.916,899.4 14.2%   
Avg. wages/employee Rs Th614.22,877.7 21.3%   
Avg. net profit/employee Rs Th-307.91,879.9 -16.4%   
INCOME DATA
Net Sales Rs m5,928132,153 4.5%  
Other income Rs m823,128 2.6%   
Total revenues Rs m6,010135,281 4.4%   
Gross profit Rs m84566,290 1.3%  
Depreciation Rs m5855,202 11.3%   
Interest Rs m1,00644,097 2.3%   
Profit before tax Rs m-66420,119 -3.3%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m998,611 1.1%   
Profit after tax Rs m-76014,701 -5.2%  
Gross profit margin %14.350.2 28.4%  
Effective tax rate %-14.942.8 -34.7%   
Net profit margin %-12.811.1 -115.2%  
BALANCE SHEET DATA
Current assets Rs m5,603122,742 4.6%   
Current liabilities Rs m6,910310,810 2.2%   
Net working cap to sales %-22.0-142.3 15.5%  
Current ratio x0.80.4 205.3%  
Inventory Days Days20623 892.2%  
Debtors Days Days8439 215.6%  
Net fixed assets Rs m9,941116,904 8.5%   
Share capital Rs m61369 16.6%   
"Free" reserves Rs m3,026272,161 1.1%   
Net worth Rs m3,087272,530 1.1%   
Long term debt Rs m5,707270,196 2.1%   
Total assets Rs m16,076856,261 1.9%  
Interest coverage x0.31.5 23.4%   
Debt to equity ratio x1.81.0 186.5%  
Sales to assets ratio x0.40.2 238.9%   
Return on assets %1.56.9 22.3%  
Return on equity %-24.65.4 -456.4%  
Return on capital %3.912.4 31.5%  
Exports to sales %24.00-   
Imports to sales %17.50-   
Exports (fob) Rs m1,424NA-   
Imports (cif) Rs m1,040NA-   
Fx inflow Rs m1,60015,200 10.5%   
Fx outflow Rs m1,1314,889 23.1%   
Net fx Rs m46910,312 4.5%   
CASH FLOW
From Operations Rs m1,180-115,975 -1.0%  
From Investments Rs m553-8,265 -6.7%  
From Financial Activity Rs m-1,644107,525 -1.5%  
Net Cashflow Rs m90-16,650 -0.5%  

Share Holding

Indian Promoters % 74.5 52.9 140.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 4.0 15.0%  
FIIs % 1.3 26.6 4.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 16.5 143.0%  
Shareholders   10,259 93,274 11.0%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Sep 13, 2019 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - GLENMARK PHARMA COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS